摘要
目的比较双重抗血小板聚集和单用药物治疗超敏C反应蛋白（hs-CRP）＜2mg/L的心绞痛患者的效果差异。方法选取因心绞痛6～48h内就诊于我院且hs-CRP＜2mg/L的患者96例，采用随机数字表法分为阿司匹林组和联合治疗组，每组48例。阿司匹林组患者口服拜阿司匹林100mg/d，联合治疗组患者口服拜阿司匹林100mg/d并加硫酸氢氯吡格雷片75mg/d，治疗后30d时对患者进行疗效评定，并通过随访对患者6个月内出现复合终点事件的情况进行统计。结果阿司匹林组总效率［81.25%（39/48）］与联合治疗组［85.42%（41/48）］差异无统计学意义（χ2=0.300，P＞0.05）。2组患者治疗后的复合终点事件差异均无统计学意义（P>0.05）。结论对于hs-CRP＜2mg/L的心绞痛患者，即心血管事件风险相对较小的患者，单一与双重抗血小板聚集治疗方案的效果无明显差异。
Objective To evaluate the feasibility of application of single and dual antiplatelet aggregation therapy in high sensitive C- reactive protein (hs- CRP) level in patients with angina pectoris. Methods Ninety- six hospitalized patients with angina 6~48 h (hs-CRP < 2 mg/L) were selected and randomly divided into single aspirin group (aspirin 100 mg/d, n=48) and aspirin plus clopidogrel combination therapy group (aspirin 100 mg/d and clopidogrel 75 mg/d, n=48). The efficacy was evaluated after 30-day treatment. Data of composite end points were analyzed by follow-up in patients within 6 months. Results The total effective rates were 85.42% for combination therapy group and 81.25% for single aspirin group.There was no significant difference in total effective rate between two groups (P > 0.05). There were no significant differences in events of composite end points in patients after treatment between two groups (P > 0.05). Conclusion For angina pectoris patients with hs-CRP < 2 mg/L, the risk of cardiovascular events is relatively little. There is no obvious difference in curative effect between single and dual antiplatelet aggreration therapies.
作者
于伟
周凤云
刘青
朱素娟
靳晓华
刘鹏
YU Wei;ZHOU Fengyun;LIU Qing;ZHU Sujuan;JIN Xiaohua;LIU Peng(Department of Cardiology Three, the People’s Hospital of Zhangqiu City, Shandong Province 250200, China)
出处
《天津医药》
CAS
2016年第8期967-969,共3页
Tianjin Medical Journal
基金
章丘市人民医院面上课题(201404)
关键词
超敏C反应蛋白
心绞痛
冠状动脉疾病
抗血小板聚集治疗
阿司匹林
硫酸氢氯吡格雷
hypersensitive C- reactive protein
angina pectoris
coronary artery disease
antiplatelet aggregation therapy
aspirin
clopidogrel hydrogen sulfate
